Plasma levels of miR‐29b and miR‐200b in type 2 diabetic retinopathy

Silva, Maria Enóia Dantas da Costa e; Polina, Evelise Regina; Crispim, Daisy; Sbruzzi, Renan Cesar; Lavinsky, Daniel; Mallmann, Felipe; Martinelli, Nidiane Carla; Canani, Luís Henrique Santos; Santos, Kátia Gonçalves dos

doi:10.1111/jcmm.14030

Cited by 34 publications

(17 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, endothelial miR-200b overexpression prevents diastolic dysfunction and endothelial-to-mesenchymal transition, preserving, therefore, cellular integrity and preventing diabetes-induced adverse myocardial structural and functional changes [131] (Table 1). Importantly, very recently, a report was published showing that levels of miR-200b are lower in patients with T2DM than in control ones [132] (Table 1). Further studies are required in order to elaborate on the different protective and/or adverse impacts that each member of the miR-200 family has in a cell and disease dependent manner in order to optimize any potential therapeutic approach.…”

Section: Micrornas (Mirnas)mentioning

confidence: 99%

MicroRNAs as Potential Pharmaco-Targets in Ischemia-Reperfusion Injury Compounded by Diabetes

Dehaini

Awada

El‐Yazbi

et al. 2019

Cells

View full text Add to dashboard Cite

Background: Ischemia-Reperfusion (I/R) injury is the tissue damage that results from re-oxygenation of ischemic tissues. There are many players that contribute to I/R injury. One of these factors is the family of microRNAs (miRNAs), which are currently being heavily studied. This review aims to critically summarize the latest papers that attributed roles of certain miRNAs in I/R injury, particularly in diabetic conditions and dissect their potential as novel pharmacologic targets in the treatment and management of diabetes. Methods: PubMed was searched for publications containing microRNA and I/R, in the absence or presence of diabetes. All papers that provided sufficient evidence linking miRNA with I/R, especially in the context of diabetes, were selected. Several miRNAs are found to be either pro-apoptotic, as in the case of miR-34a, miR-144, miR-155, and miR-200, or anti-apoptotic, as in the case of miR-210, miR-21, and miR-146a. Here, we further dissect the evidence that shows diverse cell-context dependent effects of these miRNAs, particularly in cardiomyocytes, endothelial, or leukocytes. We also provide insight into cases where the possibility of having two miRNAs working together to intensify a given response is noted. Conclusions: This review arrives at the conclusion that the utilization of miRNAs as translational agents or pharmaco-targets in treating I/R injury in diabetic patients is promising and becoming increasingly clearer.

show abstract

Section: Micrornas (Mirnas)mentioning

confidence: 99%

MicroRNAs as Potential Pharmaco-Targets in Ischemia-Reperfusion Injury Compounded by Diabetes

Dehaini

Awada

El‐Yazbi

et al. 2019

Cells

View full text Add to dashboard Cite

show abstract

“…In recent years, several works have investigated the association of miRNAs with DR (23)(24)(25)(26)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52). In circulating miRNA profiling studies, miR-27b, miR-320a, and miR-126 were validated in patients with type 1 diabetes and DR (23,42).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-1281 as a Novel Circulating Biomarker in Patients With Diabetic Retinopathy

et al. 2020

View full text Add to dashboard Cite

Objective: Recently, the role of circulating miRNAs as non-invasive biomarkers for the identification and monitoring of diabetes microvascular complications has emerged. Herein, we aimed to: identify circulating miRNAs differentially expressed in patients with and without diabetic retinopathy (DR); examine their predictive value; and understand their pathogenic impact. Methods: Pooled serum samples from randomly selected matched patients with type 2 diabetes, either with or without DR, were used for initial serum miRNA profiling. Validation of the most relevant miRNAs was thereafter conducted by RT-qPCR in an extended sample of patients with DR and matched controls. Results: Following miRNA profiling, 43 miRNAs were significantly up-or down-regulated in patients with DR compared with controls. After individual validation, 5 miRNAs were found significantly overexpressed in patients with DR. One of them, miR-1281, was the most up-regulated and appeared to be specifically related to DR. Furthermore, secreted levels of miR-1281 were increased in high glucose-cultured retinal cells, and there was evidence of a potential link between glucose-induced miR-1281 up-regulation and DR. Conclusion: Our findings suggest miR-1281 as a circulating biomarker of DR. Also, they highlight the pathogenic significance of miR-1281, providing insights for a new potential target in treating DR.

show abstract

“…Overexpression of miR-222 protects against cardiac injury and miR-17-3p promotes cardiomyocyte proliferation and increased cardiomyocyte size through directly targeting TIMP3 (Wang et al, 2018). miR-29b is one of the first miRNAs that was found to be dysregulated in retinal cells and diabetic rats exposed to high glucose concentrations, suggesting that they are involved in the development of DM (Dantas da Costa E Silva et al, 2019). A recent in vivo study showed that miR-29b is involved in regulation of glucose balance and insulin secretion through a variety of target genes and influences the pathogenesis of diabetes (Dooley et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Long Non-coding RNA H19 Suppression Protects the Endothelium Against Hyperglycemic-Induced Inflammation via Inhibiting Expression of miR-29b Target Gene Vascular Endothelial Growth Factor a Through Activation of the Protein Kinase B/Endothelial Nitric Oxide Synthase Pathway

Cheng

Chen

Wan

et al. 2019

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

It has been shown that non-coding RNAs (ncRNAs) play an important regulatory role in pathophysiological processes involving inflammation. The vascular endothelial growth factor A (VEGFA) gene also participates in the inflammatory process. However, the relationships between ncRNAs and VEGFA are currently unclear. Here, this study was designed to determine the relationship between long non-coding RNA (lncRNA) H19, mircoRNA29b (miR-29b), and VEGFA in the development of diabetes mellitus (DM). We demonstrate that H19 is upregulated and miR-29b downregulated in individuals with DM and directly binds miR-29b. VEGFA is the target of miR-29b in the vascular endothelium of individuals with DM. We found that positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress. We also found that the protein kinase B/endothelial nitric oxide synthase (AKT/eNOS) signal pathway in endothelial cells is activated through regulation of miR29b and H19 endogenous RNAs. We conclude that H19 suppression protects the endothelium against high glucose-induced inflammation and oxidative stress in endothelial cells by upregulation of miR-29b and downregulation of VEGFA through AKT/eNOS signal pathway activation. These results suggest a novel link between dysregulated ncRNA expression, inflammation, and the signaling pathway in the vascular endothelium of individuals with DM, indicating a promising strategy for preventing cardiovascular disease in such individuals.

show abstract

Plasma levels of miR‐29b and miR‐200b in type 2 diabetic retinopathy

Cited by 34 publications

References 52 publications

MicroRNAs as Potential Pharmaco-Targets in Ischemia-Reperfusion Injury Compounded by Diabetes

MicroRNAs as Potential Pharmaco-Targets in Ischemia-Reperfusion Injury Compounded by Diabetes

MicroRNA-1281 as a Novel Circulating Biomarker in Patients With Diabetic Retinopathy

Long Non-coding RNA H19 Suppression Protects the Endothelium Against Hyperglycemic-Induced Inflammation via Inhibiting Expression of miR-29b Target Gene Vascular Endothelial Growth Factor a Through Activation of the Protein Kinase B/Endothelial Nitric Oxide Synthase Pathway

Contact Info

Product

Resources

About